Abstract
The value of oligonucleotides as therapeutic agents has become increasingly apparent over the past decade (1–3). In order to be useful as therapeutic agents, oligonucleotides must possess a number of properties. These include:
-
1.
Resistance to enzyme degradation;
-
2.
The ability to enter target cells;
-
3.
A lack of interference with normal DNA and RNA processing enzymes; and
-
4.
The ability to bind to a target and alter its expression in a sequence-specific manner.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Stein, C. A. and Cohen, J. S. (1988) Oligodeoxynucleotides as inhibitors of gene expression: A Review. Cancer Res. 48, 2659–2668.
Tidd, D. M. (1991) Synthetic oligonucleotides as therapeutic agents. Br. J. Cancer 63,6–8.
Riorden, M. L. and Martin, J. C. (1991) Oligonucleotide-based therapeutics. Nature 350,442,443.
Miller, P. S. (1991) Oligonucleoside methylphosphonates as anti-sense reagents. Biotechnology 9, 358–362.
Miller, P. S. (1989) Non-ionic antisense oligonucleotides, in Oligodeoxyribo-nucleotides: Antisense Inhibitors of Gene Expression, vol. 12, Topics in Molecular and Structural Biology (Cohen, J. S., ed.) MacMillin, London, pp. 79–95.
Blake, K. R., Murakami, A., Spitz, S. A., Glave, S. A., Reddy, M. P., Ts’o, P. O. P., and Miller, P. S. (1985) Hybridization arrest of globin synthesis in rabbit reticulocyte lysates and cells by oligodeoxyribonucleoside methylphos-phonate. Biochemistry 24,6139–6142.
Chang, E. H., Zu, Y., Shinozuka, R., Zon, G., Wilson, W. D., and Strekowska, A. (1989) Comparative inhibition of ras P21 protein synthesis with phosphorus-modified antisense oligonucleotides. Anti-Cancer Drug Design 4,221–232.
Temsamani, J., Agrawal, S., and Pederson, T. (1991) Biotinylated antisense methylphosphonate oligonucleotide. J. Biol. Chem. 266,468–472.
Zamecnik, P. C, Goodchild, J., Taguchi, Y., and Sarin, P. S. (1986) Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc. Natl. Acad. Sci. USA 83,4143–4146.
Miller, P. S., McFarland, K. B., Jayaraman, K., and Ts’o, P. O. P. (1981) Biochemical and biological effects of non-ionic nucleic acid methylphosphonates. Biochemistry 20, 1874–1880.
Marcus-Sekura, C. J., Woerner, A. M., Shinozuka, K., Zon, G., and Quinnan, G. V. (1987) Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkage. Nucl. Acids Res. 15,5749–5752.
Vasanthakumar, G. and Ahmed, N. K. (1989) Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates. Cancer Commun. 1, 225–232.
Callahan, D. E., Trapane, T. L., Miller, P. S., Ts’o, P. O. P., and Kan, L.-S. (1991) Comparative circular dichroism and fluorescence studies of oligode-oxyribonucleotide and oligodeoxyribonucleoside methylphosphonate strands in duplex and triplex formation. Biochemistry 30, 1650–1655.
Hogrefe, R. I., Vaghefi, M. M., Reynold, M. A., Young, K., and Arnold, L. J. (1992) Deprotection of methylphosphonate oligonucleotides using a novel one-pot procedure. Nucl. Acids Res. submitted.
Miller, P. S., Reddy, M. P., Murakami, A., Blake, K. R., Lin, S.-B., and Agris, C. H. (1986) Solid phase syntheses of oligodeoxyribonucleoside methylphosphonate. Biochemistry 25, 5092–5095.
Letsinger, R. L., Miller, P. S., and Gram, G. W. (1968) Nucleotide chemistry. XII. Selective N-debenzoylation of N,O-polybenzoylnucleoside. Tetrahedron Lett. 22,2621–2634.
Barnett, R. W. and Letsinger, R. L. (1981) Debenzoylation of N-benzoylnucle-oside derivatives withethylenediamine/phenol. Tetrahedron Lett. 22,991–994.
Maher, L. J. and Dolnick, B. J. (1988) Comparative hybrid arrest by tandem antisense oligodeoxyribonucleotides or oligodeoxyribonucleoside methylphos-phonate in a cell-free system. Nucl. Acid Res. 16, 3341–3358.
Agrawal, S. and Goodchild, J. (1987) Oligodeoxynucleoside methylphosphonate: Synthesis and enzymatic degradation. Tetrahedron Lett. 28,3539–3542.
Sarin, P. S., Agrawal, S., Civeira, M. P., Goodchild, J. Ikeuchi, T., and Zamecnik, P. C. (1988) Inhibition of acquired immunodeficiency syndrome virus by oligonucleoside methylphosphonates. Proc. Natl. Acad. Sci. USA 85,7448–7451.
Schulhof, J. C, Molko, D., and Teoule, R. (1987) The final deprotection step in oligonucleotide synthesis reduced to a mild and rapid ammonia treatment by using labile base-protection groups. Nucl. Acid Res. 15, 397–416.
Ebright, Y., Tous, G. I., Tsao, J., Fausnaugh, J., and Stein, S. (1988) Chromatographic purification of non-ionic methylphosphonate oligodeoxyribonucleoside. J. Liquid Chromatogr. 11, 2005–2017.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Hogrefe, R.I. et al. (1993). An Improved Method for the Synthesis and Deprotection of Methylphosphonate Oligonucleotides. In: Agrawal, S. (eds) Protocols for Oligonucleotides and Analogs. Methods in Molecular Biology, vol 20. Humana Press. https://doi.org/10.1385/0-89603-281-7:143
Download citation
DOI: https://doi.org/10.1385/0-89603-281-7:143
Publisher Name: Humana Press
Print ISBN: 978-0-89603-281-1
Online ISBN: 978-1-59259-507-5
eBook Packages: Springer Protocols